Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by Claridgeon Jun 19, 2019 2:28pm
66 Views
Post# 29840961

RE:RE:RE:RE:RE:RE:Sesen (SESN.Q)

RE:RE:RE:RE:RE:RE:Sesen (SESN.Q)StevenBirch ... And to show you how Bunge was so frustrated, he then posted that he had lost 84,000$ (on paper).  That's when he continued vomitting on Roger and posted that Roger was lacking negocation skills later on.  This went on for many months.

Bungee is lacking many more things, when reading his posts.  His posts lack substance, lack perspectives, lack data.   I asked him many times to put more "meat" into his posts so we can exchange on a more solid ground.  He's only interested in superficial and arrogant comments ("Executive" type of comments) that bring nothing to mature investment discussions.

Reading Bunge at that moment, he was posting that TLT could have negociated a much better deal.  When challenged on what reality and arguments, Bunge was never able to provide more info!  The reality is that at that moment, TLT didn't even have a drug manufacturer!!!  Hard to have a best in a first negociation with US deep-pockets.

__________________

Claridge - (6/19/2019 11:05:08 AM) 

RE:Sesen (SESN.Q)

Xena555 ... Good input.

And some here in Feb. 2015 were treating Roger as one lacking negociation skills (the exact words of Bunge back then) when he did a pp @-20%, when in fact , we had not even a drug manufacturer and had just applied for a our first patent!  Funny, we have 7 months left to have 19M warrants @0.54$ from those 60 months warrants.

SESN is now in a Ph. 3!  And they have to do one @-20%.   The stock is down -22% today.

20,410,000 shares of its common stock and warrants to purchase 20,410,000 shares of its common stock at a public offering price of $1.47 per share and accompanying warrant.

Looks like we had/still have some arm-chair quarterbacks.


*1:  Feb 2015  (TLT was trading @0.53$) ... TLT pp = $0.44 per Unit for aggregate gross proceeds of approximately $8,000,000.   Each Unit consists of one common share and one common share purchase warrant. Each Warrant entitles the holder to acquire an additional Common Share at a price of $0.54 for a period of 60 months.

Theralase Manufactures High Purity Anti-Cancer Drug

May 12, 2015

Theralase Files US Patent Application for Increased Targeting of Photo Dynamic Therapy

January 20, 2015


As of April 17, 2019, there were 35,639,705 warrants outstanding. Each whole warrant entitles the holder thereof to purchase one additional common share. 

The warrants are exercisable as follows: 19,071,940 at a price of $0.54 until March 3, 2020.


_______________

xena555 - (6/19/2019 9:42:13 AM) 

Sesen (SESN.Q)

SESN did a financing, priced it this morning. 20% discount to closing price, full warrant. $30mm US$

Bullboard Posts